{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:22:56Z","timestamp":1792678976277,"version":"4.5.0"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2022,2,1]]},"DOI":"10.1001\/jamainternmed.2021.7457","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T16:01:47Z","timestamp":1641312107000},"page":"185","source":"Crossref","is-referenced-by-count":34,"title":["Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019"],"prefix":"10.1001","volume":"182","author":[{"given":"Tianna","family":"Zhou","sequence":"first","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Liu","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket S.","family":"Dhruva","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, University of California, San Francisco, San Francisco"},{"name":"Division of Cardiology, San Francisco VA Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay D.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Health Care Delivery Research, Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut"},{"name":"Yale National Clinicians Scholar Program, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina M.","family":"Berg","sequence":"additional","affiliation":[{"name":"Center on Aging, University of Connecticut School of Medicine, Farmington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Yale National Clinicians Scholar Program, Yale School of Medicine, New Haven, Connecticut"},{"name":"Section of General Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"},{"name":"Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"ioi210081r2","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/(ISSN)1532-5415","article-title":"Risk factors for adverse drug events among older adults in the ambulatory setting.","volume":"52","author":"Field","year":"2004","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"ioi210081r3","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jama.289.9.1107","article-title":"Incidence and preventability of adverse drug events among older persons in the ambulatory setting.","volume":"289","author":"Gurwitz","year":"2003","journal-title":"JAMA"},{"issue":"13","key":"ioi210081r4","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1001\/jama.289.13.1652","article-title":"Drug-drug interactions among elderly patients hospitalized for drug toxicity.","volume":"289","author":"Juurlink","year":"2003","journal-title":"JAMA"},{"issue":"10","key":"ioi210081r5","doi-asserted-by":"publisher","first-page":"M554","DOI":"10.1093\/gerona\/55.10.M554","article-title":"Polypharmacy and hospitalization among older home care patients.","volume":"55","author":"Flaherty","year":"2000","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"10","key":"ioi210081r7","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jclinepi.2012.05.005","article-title":"Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice.","volume":"65","author":"Shippee","year":"2012","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"ioi210081r9","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/MLR.0b013e3182162afb","article-title":"Medicare Part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007.","volume":"49","author":"Briesacher","year":"2011","journal-title":"Med Care"},{"issue":"6","key":"ioi210081r10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/MLR.0b013e3181dbd8d3","article-title":"Out-of-pocket burden of health care spending and the adequacy of the Medicare Part D low-income subsidy.","volume":"48","author":"Briesacher","year":"2010","journal-title":"Med Care"},{"issue":"15","key":"ioi210081r11","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJMp1908688","article-title":"Proposals to redesign Medicare Part D\u2014easing the burden of rising drug prices.","volume":"381","author":"Dusetzina","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"ioi210081r12","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1001\/jamainternmed.2017.1885","article-title":"Association of prescription drug price rebates in Medicare Part D with patient out-of-pocket and federal spending.","volume":"177","author":"Dusetzina","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"6","key":"ioi210081r14","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1001\/jama.294.6.716","article-title":"Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance.","volume":"294","author":"Boyd","year":"2005","journal-title":"JAMA"},{"issue":"4","key":"ioi210081r17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1215\/03616878-8970810","article-title":"Prescription drug priorities under the Biden administration.","volume":"46","author":"Gavulic","year":"2021","journal-title":"J Health Polit Policy Law"},{"issue":"9","key":"ioi210081r18","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1001\/jama.2020.1012","article-title":"Changes in list prices, net prices, and discounts for branded drugs in the US, 2007-2018.","volume":"323","author":"Hernandez","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"ioi210081r19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.35064","article-title":"Trends in within-class changes in US average wholesale prices for brand-name medications for common conditions from 2015 to 2020.","volume":"4","author":"Liu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ioi210081r20"},{"issue":"25","key":"ioi210081r21","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1161\/CIR.0b013e3182776f83","article-title":"2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.","volume":"126","author":"Fihn","year":"2012","journal-title":"Circulation"},{"issue":"6","key":"ioi210081r24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198674","article-title":"Medicare Part D prescribing for direct oral anticoagulants in the United States: cost, use and the \u201crubber effect\u201d.","volume":"13","author":"Ziakas","year":"2018","journal-title":"PLoS One"},{"issue":"19","key":"ioi210081r25","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"ioi210081r26","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee.","volume":"77","author":"Maddox","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"ioi210081r27","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1089\/dia.2019.0213","article-title":"Adoption of new glucose-lowering medications in the U.S.\u2014the case of SGLT2 inhibitors: nationwide cohort study.","volume":"21","author":"McCoy","year":"2019","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"ioi210081r28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.35792","article-title":"Comparison of diabetes medications used by adults with commercial insurance vs Medicare Advantage, 2016 to 2019.","volume":"4","author":"McCoy","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"ioi210081r29","doi-asserted-by":"crossref","DOI":"10.5600\/mmrr.003.03.b02","article-title":"Multiple chronic conditions among Medicare beneficiaries: state-level variations in prevalence, utilization, and cost, 2011.","volume":"3","author":"Lochner","year":"2013","journal-title":"Medicare Medicaid Res Rev"},{"issue":"5","key":"ioi210081r30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/19371918.2020.1785981","article-title":"Did the Medicare prescription drug program lead to new racial and ethnic disparities? examining long-term changes in prescription drug access among minority populations.","volume":"35","author":"Chakravarty","year":"2020","journal-title":"Soc Work Public Health"},{"issue":"11","key":"ioi210081r31","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.37765\/ajmc.2020.88531","article-title":"Differences in spending for diabetes and multiple chronic conditions in Michigan Medicare beneficiaries.","volume":"26","author":"Clements","year":"2020","journal-title":"Am J Manag Care"},{"issue":"25","key":"ioi210081r32","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.119.041974","article-title":"Cost-related medication nonadherence in adults with atherosclerotic cardiovascular disease in the United States, 2013 to 2017.","volume":"140","author":"Khera","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"ioi210081r33","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jacc.2016.06.005","article-title":"Assessing the impact of medication adherence on long-term cardiovascular outcomes.","volume":"68","author":"Bansilal","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"ioi210081r36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamainternmed.2018.0990","article-title":"Trends in use and expenditures of brand-name atorvastatin after introduction of generic atorvastatin.","volume":"178","author":"Warraich","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"6","key":"ioi210081r37","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1007\/s11606-019-05432-6","article-title":"Medicare formulary coverage of brand-name drugs and therapeutically interchangeable generics.","volume":"35","author":"Vijay","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"2","key":"ioi210081r39","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"issue":"12","key":"ioi210081r40","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/jamainternmed.2013.817","article-title":"Cost consideration in the clinical guidance documents of physician specialty societies in the United States.","volume":"173","author":"Schwartz","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"7","key":"ioi210081r41","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.2372","article-title":"Drug pricing reform in 2021\u2014going big or going bipartisan?","volume":"2","author":"Dusetzina","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"22","key":"ioi210081r42","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1161\/CIR.0000000000000042","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.","volume":"129","author":"Anderson","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"ioi210081r44","first-page":"32","article-title":"Polypharmacy: evaluating risks and deprescribing.","volume":"100","author":"Halli-Tierney","year":"2019","journal-title":"Am Fam Physician"},{"issue":"12","key":"ioi210081r45","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jamainternmed.2018.4720","article-title":"Assessment of attitudes toward deprescribing in older Medicare beneficiaries in the United States.","volume":"178","author":"Reeve","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"1","key":"ioi210081r48","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014287","article-title":"Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries.","volume":"7","author":"Morgan","year":"2017","journal-title":"BMJ Open"},{"issue":"6","key":"ioi210081r50","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s11606-016-3612-7","article-title":"Variations in patients\u2019 perceptions and use of generic drugs: results of a national survey.","volume":"31","author":"Kesselheim","year":"2016","journal-title":"J Gen Intern Med"},{"issue":"11","key":"ioi210081r51","doi-asserted-by":"publisher","first-page":"817","DOI":"10.7326\/M18-0965","article-title":"Medicare beneficiary out-of-pocket costs for generic cardiovascular medications available through $4 generic drug discount programs.","volume":"169","author":"Liu","year":"2018","journal-title":"Ann Intern Med"},{"issue":"10","key":"ioi210081r52","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jamainternmed.2021.3366","article-title":"Comparison of spending on common generic drugs by Medicare vs Costco members.","volume":"181","author":"Trish","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"6","key":"ioi210081r53","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamainternmed.2021.0733","article-title":"Characteristics of copayment offsets for prescription drugs in the United States.","volume":"181","author":"Sen","year":"2021","journal-title":"JAMA Intern Med"},{"key":"ioi210081r49","author":"Chandra"},{"key":"ioi210081r1","unstructured":"Centers for Medicare & Medicaid Services. Chronic conditions among Medicare beneficiaries: chartbook: 2017 edition. Accessed August 20, 2020. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Chronic-Conditions\/Downloads\/cc_charts.zip"},{"key":"ioi210081r6","unstructured":"Koma? W, Neuman? T, Jacobson? G, Smith? K. Medicare beneficiaries\u2019 financial security before the coronavirus pandemic. Kaiser Family Foundation. April 24, 2020. Accessed June 19, 2021. https:\/\/www.kff.org\/medicare\/issue-brief\/medicare-beneficiaries-financial-security-before-the-coronavirus-pandemic\/"},{"key":"ioi210081r8","unstructured":"Social Security Administration. Compilation of the Social Security laws: title XVIII\u2014health insurance for the aged and disabled. Social Security Administration; 2021. Accessed July 19, 2021. https:\/\/www.ssa.gov\/OP_Home\/ssact\/title18\/1800.htm"},{"key":"ioi210081r13","unstructured":"Pearson? CF, Brantley? K, Frieder? M. Majority of drugs now subject to coinsurance in Medicare Part D plans. Avalere Health. March 10, 2016. Accessed March 14, 2021. https:\/\/avalere.com\/press-releases\/majority-of-drugs-now-subject-to-coinsurance-in-medicare-part-d-plans"},{"key":"ioi210081r15","unstructured":"US Bureau of Labor Statistics. CPI inflation calculator. US Bureau of Labor Statistics. Accessed June 19, 2020. https:\/\/www.bls.gov\/data\/inflation_calculator.htm"},{"key":"ioi210081r16","unstructured":"Foster? R, Clemens? MK. Additional information regarding comparisons of beneficiary income and out-of-pocket costs for Medicare supplementary medical insurance. Memorandum. Office of the Actuary, Centers for Medicare & Medicaid Services, Department of Health & Human Services. March 25, 2008. Accessed July 19, 2021. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/ReportsTrustFunds\/downloads\/Beneficiaryoop.pdf"},{"key":"ioi210081r22","unstructured":"Cubanski? BJ, Biniek? JF, Rae? M, Damico? A, Frederiksen? B, Salganicoff? A. Mail delays could affect mail-order prescriptions for millions of Medicare Part D and large employer plan enrollees. Kaiser Family Foundation. August 20, 2020. Accessed July 19, 2021. https:\/\/www.kff.org\/coronavirus-covid-19\/issue-brief\/mail-delays-could-affect-mail-order-prescriptions-for-millions-of-medicare-part-d-and-large-employer-plan-enrollees\/"},{"key":"ioi210081r23","unstructured":"Cubanski? J, Neuman? T, Damico? A. Closing the Medicare Part D coverage gap: trends, recent changes, and what\u2019s ahead. Kaiser Family Foundation. August 21, 2018. Accessed June 19, 2021. https:\/\/www.kff.org\/medicare\/issue-brief\/closing-the-medicare-part-d-coverage-gap-trends-recent-changes-and-whats-ahead"},{"key":"ioi210081r34","unstructured":"Kaiser Family Foundation. Poll: nearly 1 in 4 Americans taking prescription drugs say it\u2019s difficult to afford their medicines, including larger shares among those with health issues, with low incomes and nearing Medicare age. Kaiser Family Foundation. March 1, 2019. Accessed June 19, 2021. https:\/\/www.kff.org\/health-costs\/press-release\/poll-nearly-1-in-4-americans-taking-prescription-drugs-say-its-difficult-to-afford-medicines-including-larger-shares-with-low-incomes\/"},{"key":"ioi210081r35","unstructured":"Council for Informed Drug Spending Analysis. High drug prices and patient costs: millions of lives and billions of dollars lost. November 18, 2020. Accessed July 19, 2021. https:\/\/www.cidsa.org\/publications\/xcenda-summary"},{"key":"ioi210081r38","unstructured":"Cubanski? J, Neuman? T, Orgera? K, Damico? A. No limit: Medicare Part D enrollees exposed to high out-of-pocket drug costs without a hard cap on spending. Issue brief. The Henry J. Kaiser Family Foundation. November 2017. Accessed July 19, 2021. https:\/\/files.kff.org\/attachment\/Issue-Brief-No-Limit-Medicare-Part-D-Enrollees-Exposed-to-High-Out-of-Pocket-Drug-Costs-Without-a-Hard-Cap-on-Spending"},{"key":"ioi210081r43","unstructured":"National Academy for State Health Policy. Comparison of provisions of states\u2019 current drug affordability review board proposals. National Academy for State Health Policy. Updated March 19, 2019. Accessed July 19, 2021. https:\/\/www.nashp.org\/comparison-of-bills-creating-state-prescription-drug-affordability-review-boards\/"},{"key":"ioi210081r46","unstructured":"American Geriatrics Society. Publications and tools: AGS guidelines, recommendations, and position statements. 2021. Accessed November 23, 2021. https:\/\/www.americangeriatrics.org\/publications-tools"},{"key":"ioi210081r47","unstructured":"American Academy of Family Physicians. Clinical practice guidelines: choosing Wisely. 2021. Accessed November 23, 2021. https:\/\/www.aafp.org\/family-physician\/patient-care\/clinical-recommendations\/clinical-practice-guidelines\/choosing-wisely.html"},{"key":"ioi210081r54","unstructured":"Kaiser Family Foundation. An overview of the Medicare Part D prescription drug benefit. Kaiser Family Foundation. October 13, 2021. Accessed June 19, 2021. https:\/\/www.kff.org\/medicare\/fact-sheet\/an-overview-of-the-medicare-part-d-prescription-drug-benefit\/"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2787778\/jamainternal_zhou_2022_oi_210081_1643648283.14352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T16:14:29Z","timestamp":1644250469000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2787778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2021.7457","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}